Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ717MR)

This product GTTS-WQ717MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ717MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3866MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ14427MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ9573MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ795MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ14362MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ6530MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ1696MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ2405MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW